MedTrace Logo

Enhancing Influenza Vaccination in Seniors With TLR (Toll Like Receptor) Agonists

NCT01737580 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2013-08-28

No results posted yet for this study

Summary

The application of the TLR7/8 (Toll Like Receptor) agonist gel (immune response helper) resiquimod will enhance the immune response to the intradermal influenza vaccine in seniors 65-75 years of age.

Conditions

  • Influenza Vaccination in Seniors

Interventions

DRUG

resiquimod

DRUG

placebo gel

Sponsors & Collaborators

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Jan P Dutz, MD · University of British Columbia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01737580 on ClinicalTrials.gov